Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000919574-26-004748
Filing Date
2026-08-04
Accepted
2026-08-04 10:06:05
Documents
2
X0202

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 10829
2 p15038313exh_99-1.htm EX-99.1 3351
  Complete submission text file 0000919574-26-004748.txt   16030
Mailing Address 100 CAMPUS DRIVE FLORHAM PARK NJ 07932
Business Address 100 CAMPUS DRIVE FLORHAM PARK NJ 07932 (608) 441-8120
Cellectar Biosciences, Inc. (Subject) CIK: 0001279704 (see all company filings)

EIN.: 043321804 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-85798 | Film No.: 261236166
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 1 ROCKEFELLER PLAZA, SUITE 1205 NEW YORK NY 10020
Business Address 1 ROCKEFELLER PLAZA, SUITE 1205 NEW YORK NY 10020 212-608-3300
Empery Asset Management, LP (Filed by) CIK: 0001469336 (see all company filings)

EIN.: 262107121 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G